Starting July 1, 2026, eligible Medicare Part D patients can access Eli Lilly’s obesity medications, including Zepbound and Foundayo, for $50 per month through the newly launched Medicare GLP-1 Bridge program. This pathway marks the first time Medicare Part D has provided broad coverage for weight management GLP-1 medications, according to an announcement from Eli Lilly and Company.
How the Medicare GLP-1 Bridge Program Works
The program creates a specific coverage pathway for patients who meet clinical criteria set by the Centers for Medicare & Medicaid Services (CMS). According to Eli Lilly, the program is available to patients who are 18 or older, possess qualifying Medicare Part D drug coverage, and have a Body Mass Index (BMI) of 35 or higher, or 27 or higher with weight-related medical conditions. Ilya Yuffa, president of Lilly USA, stated that approximately 20 million Medicare patients may meet these clinical requirements. Coverage for these medications is scheduled to run through December 31, 2027.
Comparing Treatment Options: Oral Pills vs. Injectables
Patients gain a choice between two distinct delivery methods under this initiative. Foundayo (orforglipron) is a once-daily oral pill that does not require planning around food or drink, while Zepbound (tirzepatide) is an injectable medication. According to clinical data provided by Eli Lilly, both medications are indicated for chronic weight management when paired with a reduced-calorie diet and increased physical activity. In separate Phase 3 trial analyses, both drugs showed meaningful weight loss in adults aged 65 and older with safety profiles consistent with younger populations.
Steps to Access Weight Management Medications
To begin the process, patients must first consult their healthcare provider to determine if Foundayo or Zepbound is clinically appropriate. According to the company, the process involves five steps: discussing the medication with a doctor, sending the prescription to a pharmacy like LillyDirect, completing a prior authorization, and meeting the established clinical criteria. Once approved, the monthly cost is set at $50. Patients can find more information on the official Medicare website regarding coverage for weight loss drugs.
Future Trends in Obesity Care for Seniors
The introduction of the GLP-1 Bridge program reflects a shift in how chronic weight management is addressed within the aging population. Historically, Medicare has not broadly covered weight loss medications despite data showing that two in five U.S. adults aged 65 and older live with obesity. This move signals a broader trend toward treating obesity as a chronic, complex disease rather than a lifestyle issue. As more data emerges from trials like ATTAIN-1 and SURMOUNT-1, the focus is increasingly on long-term cardiovascular health and the reduction of comorbidities like obstructive sleep apnea and hypertension.
Frequently Asked Questions
- Can I use this program if I have type 2 diabetes? No. Patients currently receiving GLP-1s for type 2 diabetes are ineligible, as these conditions are typically already covered under existing Part D plans, according to CMS requirements.
- Are there side effects I should watch for? Yes. Both medications carry warnings regarding potential thyroid tumors, including thyroid cancer. Other common side effects include nausea, vomiting, and stomach pain. Consult your doctor for a full safety summary.
- How long will the program last? The Medicare GLP-1 Bridge program is currently scheduled to operate through December 31, 2027.
Are you or a loved one considering these new treatment options? Join the conversation below and share your questions about navigating the Medicare enrollment process. For more updates on healthcare policy and medication access, subscribe to our weekly health newsletter.
